Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Mikro7 is an artificial microbiome product being developed by BiomicaLabs, a biotech subsidiary of the FUTRUE healthcare group. The product is designed to treat serious diseases by utilizing laboratory-engineered microbial consortia for targeted therapeutic transfer. BiomicaLabs aims to initiate clinical trials for the Mikro7 platform in 2025, with the goal of fundamentally addressing disease through the modulation of the human microbiome. While specific indications and microbial strains have not been publicly detailed, the platform represents a shift toward precision microbiome-based medicine.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Mikro7.